This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Baumhackl, U Articles by Mertin, J Search for Related Content PubMed PubMed Citation Articles by Baumhackl, U Articles by Mertin, J Social Bookmarking                   What's this?

A randomized, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

Department of Neurology, Central Clinic, St. Poelten, Austria, neurologie{at}kh-st-poelten.at

L Kappos

MS-MRI Evaluation Centre, University Hospital Basel, Basel, Switzerland

E W Radue

MS-MRI Evaluation Centre, University Hospital Basel, Basel, Switzerland

P Freitag

MS-MRI Evaluation Centre, University Hospital Basel, Basel, Switzerland

A Guseo

Department of Neurology, Central Hospital Székesfehérvár, Hungary

M Daumer

Institute for Statistics, University of Munich, Munich, Germany

J Mertin

Department of Neurology, Clinic Bad Windsheim, Germany

Oral administration of hydrolytic enzymes (HE), such as bromelain, trypsin and rutosid, may have beneficial effects on the clinical course of neurological symptoms related to multiple sclerosis (MS). This is supported by a complete protection by HE from experimental allergic encephalomyelitis, an animal model related to MS. Three hundred and one patients with relapsing MS were enrolled in a double-blind, placebo-controlled trial. No treatment effect between the placebo and the HE groups was found either for clinical or MRI parameters.

Key Words: hydrolytic enzymes • multiple sclerosis • therapy

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?